RXST

+ Watchlist + Portfolio

RxSight, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $6.16
52-Week Range: $4.48 – $13.22
Market Cap: $253.30M
P/E (TTM): —
EPS (TTM): -1.14
Dividend Yield: —

Advanced Metrics

Price/Book: 0.94
PEG Ratio: —
Return on Equity: -17.34%
Return on Assets: -10.41%
Gross Margin: 77.50%
Operating Margin: -40.81%
Profit Margin: -36.80%
Current Ratio: 4.07
Debt/Equity: 0.04
Total Debt: $10.58M
Free Cash Flow: $-6.73M
Revenue Growth: 0.30%
Earnings Growth: —
Enterprise Value: $58.00M

RXST Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$49.01M	$89.08M	$139.93M	$134.48M
Cost of Revenue	$27.68M	$35.31M	$40.98M	$31.47M
Gross Profit	$21.33M	$53.77M	$98.94M	$103.01M
Research & Development	$25.98M	$29.05M	$34.37M	$38.55M
Selling, General & Admin	$58.66M	$74.80M	$101.43M	$112.65M
Operating Expenses	$84.65M	$103.85M	$135.80M	$151.20M
Operating Income	-$63.32M	-$50.09M	-$36.86M	-$48.19M
EBITDA	-$57.78M	-$41.20M	-$23.81M	-$35.59M
Pretax Income	-$66.75M	-$48.59M	-$27.41M	-$38.88M
Income Tax	$9.00K	$20.00K	$50.00K	$66.00K
Net Income	-$66.76M	-$48.61M	-$27.45M	-$38.94M
Diluted EPS	-2.41	-1.41	-0.71	-0.95
Diluted Shares	27.66M	34.46M	38.87M	40.85M

RXST Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$11.83M	$9.69M	$16.71M	$19.95M
Receivables	$10.96M	$20.28M	$30.05M	$23.38M
Inventory	$14.84M	$17.42M	$22.01M	$31.56M
Current Assets	$134.56M	$168.41M	$293.82M	$287.46M
Total Assets	$150.16M	$182.55M	$318.56M	$311.81M
Current Liabilities	$17.24M	$20.90M	$25.88M	$26.25M
Long-Term Debt	$40.17M	—	—	—
Total Debt	$44.99M	$3.01M	$12.30M	$11.04M
Total Liabilities	$60.26M	$22.19M	$37.33M	$36.13M
Retained Earnings	-$546.03M	-$594.64M	-$622.10M	-$661.04M
Shareholders' Equity	$89.90M	$160.36M	$281.24M	$275.68M
Working Capital	$117.32M	$147.50M	$267.95M	$261.21M
Net Debt	$28.34M	—	—	—

RXST Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$58.85M	-$41.59M	-$16.95M	-$15.51M
Capital Expenditure	-$2.39M	-$4.81M	-$5.44M	-$3.83M
Free Cash Flow	-$61.24M	-$46.41M	-$22.39M	-$19.34M
Depreciation & Amortisation	$4.02M	$4.08M	$3.58M	$3.27M
Stock-Based Compensation	$11.40M	$15.75M	$24.64M	$31.61M
Investing Cash Flow	$39.95M	-$22.13M	-$99.31M	$16.89M
Financing Cash Flow	$6.33M	$61.52M	$123.32M	$1.86M
Net Change in Cash	-$12.57M	-$2.20M	$7.06M	$3.24M

RXST Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$37.90M	$33.64M	$30.34M	$32.61M	$30.89M
Cost of Revenue	$9.57M	$8.45M	$6.11M	$7.34M	$7.39M
Gross Profit	$28.33M	$25.19M	$24.23M	$25.26M	$23.50M
Research & Development	$10.37M	$10.22M	$9.06M	$8.90M	$9.47M
Selling, General & Admin	$28.64M	$28.98M	$27.34M	$27.70M	$31.86M
Operating Expenses	$39.00M	$39.19M	$36.41M	$36.60M	$41.33M
Operating Income	-$10.67M	-$14.00M	-$12.18M	-$11.34M	-$17.83M
EBITDA	-$7.38M	-$10.97M	-$8.95M	-$8.29M	-$15.04M
Pretax Income	-$8.17M	-$11.75M	-$9.81M	-$9.15M	-$15.88M
Income Tax	$18.00K	$32.00K	$10.00K	$5.00K	$6.00K
Net Income	-$8.19M	-$11.79M	-$9.82M	-$9.15M	-$15.88M
Diluted EPS	-0.20	-0.29	-0.24	-0.22	-0.38
Diluted Shares	40.51M	40.74M	40.97M	41.18M	41.31M

RXST Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$28.00M	$40.35M	$29.63M	$19.95M	$17.57M
Receivables	$30.96M	$28.06M	$24.15M	$23.38M	$22.44M
Inventory	$23.57M	$25.06M	$28.95M	$31.56M	$34.87M
Current Assets	$288.41M	$283.87M	$283.88M	$287.46M	$279.23M
Total Assets	$313.04M	$309.01M	$308.53M	$311.81M	$303.99M
Current Liabilities	$22.74M	$20.38M	$22.29M	$26.25M	$27.38M
Total Debt	$12.04M	$11.71M	$11.56M	$11.04M	$10.83M
Total Liabilities	$33.73M	$31.00M	$32.56M	$36.13M	$36.70M
Retained Earnings	-$630.28M	-$642.07M	-$651.89M	-$661.04M	-$676.92M
Shareholders' Equity	$279.32M	$278.01M	$275.97M	$275.68M	$267.30M
Working Capital	$265.67M	$263.49M	$261.59M	$261.21M	$251.85M

RXST Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$8.83M	-$4.38M	-$1.19M	-$1.12M	-$10.89M
Capital Expenditure	-$575.00K	-$1.54M	-$581.00K	-$1.14M	-$759.00K
Free Cash Flow	-$9.41M	-$5.91M	-$1.77M	-$2.25M	-$11.65M
Depreciation & Amortisation	$785.00K	$776.00K	$854.00K	$851.00K	$834.00K
Stock-Based Compensation	$7.14M	$8.55M	$8.11M	$7.82M	$7.95M
Investing Cash Flow	$20.86M	$14.65M	-$9.00M	-$9.61M	$8.85M
Financing Cash Flow	-$735.00K	$2.06M	-$530.00K	$1.06M	-$336.00K
Net Change in Cash	$11.29M	$12.34M	-$10.72M	-$9.67M	-$2.38M

Market Snapshot

About

RxSight, Inc. is a commercial-stage medical technology company focused on revolutionizing cataract surgery outcomes. The company developed the Light Adjustable Lens, the first and only intraocular lens that can be customized after implantation to improve visual acuity. RxSight combines innovative lens materials with proprietary light delivery systems to optimize patient vision.